Choice of HMA for newly diagnosed TP53-mutant AML: a COMMAND registry study
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2026-01-21
Просмотров: 8
Talha Badar, MD, Mayo Clinic, Rochester, MN, discusses a COMMAND registry analysis comparing azacitidine and decitabine-based regimens for newly diagnosed TP53-mutated acute myeloid leukemia (AML). Dr Badar explains that although decitabine was associated with slightly higher response rates, both agents produced comparable survival outcomes, supporting either hypomethylating agent (HMA) as a reasonable frontline option. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
